Background: Publicly available genomic data are a valuable resource for studying normal human variation and disease, but these data are often not well labeled or annotated. The lack of phenotype information for public genomic data severely limits their utility for addressing targeted biological questions.
: Missing phenotype information A.Phenotype information is critical to answer questions about biology using expression data. B. This critical information is missing for many samples within within the SRA (blue boxes). Note that sample phenotype information begins with the 6,620th row, as this is the first row in the dataset for which sex and tissue are available for the same sample. C. Missingness is limited within the GTEx data. Expression data from samples with accompanying phenotype information are used to build the predictors. ERs = expressed regions without such critical sample information, downstream analytic utility is limited. Further, as these data were initially generated in many different labs, analysis using these data must be concerned about unwanted sources of variation affecting their analyses [11] . It is critical to have technical phenotype information available including such as sequencing strategy employee information across samples.
To address this missing phenotype issue, we have built predictors from the expression estimates themselves for a number of biological and technical phenotypes 2. Using the data within recount2 [9] , which includes samples from the Genotype-Tissue Expression Project (GTEx) [12, 13] (N=9,538), The Cancer Genome Atlas (TCGA) ( http://cancergenome.nih.gov/) (N=11,284), and the sequence read archive (SRA) (N=49,657) [4] , we have identified regions that are able to accurately predict (1) sex, (2) sample source (whether the sample was generated from a cell line or tissue sample), (3) tissue, and (4) the sequencing strategy (single or paired end) employed. With Figure 2 : General approach to phenotype prediction To predict phenotype information, the training data are first randomly divided and the predictor is built. Accuracy is first tested in the training. Upon achieving sufficient accuracy (≥85%), the predictor is tested in the remaining half of the training data set. Phenotypes can then be predicted across all samples within the data set. Finally, we highlight three possible use cases to demonstrate how the phenotypes predicted can be useful in both their own right as well as for use in future analyses. First, there has historically been a sex bias in biomedical research, such that in both humans and in mice, samples from males are utilized more frequently than females [14, 15] . Accordingly, we demonstrate how predicted phenotypes can be used to characterize the overall breakdown by sex for samples in the SRA.
Second, we demonstrate how the phenotypes we have predicted can be used to identify studies whose data may be of particular interest to researchers for their analyses. Last, after identifying a study of interest, we demonstrate how predicted phenotypes can be incorporated into an expression study to gain insight into biology.
Results

Phenotype prediction
We harnessed the inherent variability of expression data to accurately predict important biological (i.e. sex, sample origin, tissue) and technical (i.e. sequencing strategy) phenotypes from the expression data itself. All phenotype predictors were built using the data available in recount2 [9] .
Data included within this resource include RNA-seq data from (1) the GTEx Project (N=9,538), TCGA (N=11,284), and the SRA (N=49,657). Region-level expression estimates [16, 7] , which are annotation-agnostic, were used for prediction. To build the predictors included here and to enable future predictors to be built using this approach, we have developed the R package phenopredict, which includes all the necessary functions to build and test predictors from expression data. Number of both samples used and regions included for predictions included herein are summarized in Supplementary Table S1 . Figure 3 : Prediction accuracy Predictors for critical phenotype information were built from expression data available in recount2 for A. sex B. tissue C. sequencing strategy and D. sample source. Samples for which reported phenotype information is available were used to determine predictor accuracy. GTEx data are in purple, TCGA in pink, and SRA in teal.
Sex prediction
Sex prediction from RNA-seq data benefits from the biological fact that males and females differ in their sex chromosome composition. To build a predictor for sex from expression data, the GTEx data were first split into a training set (N=4,769) and a test set (N=4,769). The 40 regions (20 each from the X and Y chromosomes) that best discriminated males and females in the GTEx training data were selected and the predictor built. In the GTEx training data, when applying the predictor to the data upon which it was trained, the resubstitution error (see Methods section 4.7) was 0.1%. Sex prediction was then carried out in the GTEx test set, an expression data set in which the data were generated by the same consortia but whose samples were not included to build the predictor. Prediction accuracy was 99.8% in these data. Sex prediction was carried out in data from TCGA (N=11,284), a completely independent and well-characterized data set, where prediction accuracy was 94.2%, and in the SRA samples for which sex information was available (N=3,640), where accuracy was 84.3% ( Figure 3A ).
Tissue prediction
Tissue prediction is more complex than sex prediction for two reasons: (1) region selection must be carried out across all chromosomes (not just the sex chromosomes) and (2) there are more than two levels for which a predictor must be built. In the case of the data in recount2 [9] , the GTEx training data include information for 30 different tissues. For each tissue, regions with distinct expression profiles relative to all the other tissues in the data set were selected for inclusion in the predictor. For these analyses, 1,057 regions were selected across the autosomes and the sex chromosomes. Accuracy was assessed as above for the GTEx and TCGA data: using the percentage of samples whose tissues correctly predicted from their expression data as our metric.
Here, tissue prediction was correct in the GTEx training set 96.1% of the time (3.9% re-substitution error). Accuracy for tissue prediction was 95.1% in the GTEx test set (N=4,769) and 64.7% in the TCGA data (N=7,193) ( Figure 3B ). We note, however, that TCGA is a cancer data set that includes samples from cancerous tissues as well as healthy control tissue. When this analysis was stratified to separate healthy tissue samples from cancer tissue samples, prediction was accurate 88.6% of the time in healthy tissue (N=613) and 62.5% of the time in cancerous tissue (N=6,705) 6 2017/06/03
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( Supplementary Figure 1 ), suggesting that altered expression within cancerous tissue samples may benefit from a separate tissue predictor. Assessment in SRA was less direct as tissue information was infrequently available in the metadata available from the SRA. Instead, to find a metric to which we could compare our predicted tissue types in SRA, a natural language processing tool, sharq (http://www.cs.cmu.edu/~ckingsf/sharq/) was employed. sharq was previously used to scrape the abstracts for a subset of studies included in the SRA, extracting its best guess as to the tissue used for study from each. Using this tool, tissue type was assigned to 8,951 SRA samples. These predictions ('sharq beta') were previously made available in recount2 [9] . Comparison between the sharq beta predictions and our tissue predictions from expression data were concordant in 47.1% of the SRA samples ( Figure 3B ). By using NLP to predict tissue, accuracy within the SRA is likely a lower bound, and one could expect to see improved accuracy, had reported tissue been directly available for comparison.
To assess this claim directly, we compared predictions from the expression data and sharq beta predictions to reported phenotypes for the subset of SRA samples where tissue was reported (N=10,830). Among these samples, there were 336 unique reported tissues within the SRA with 1,442 (13.3%) and 1,496 (13.8%) samples directly matching the predicted tissue from the expression data and sharq beta predictions, respectively. This relatively low concordance often reflects nonuniform or distinct coding within the SRA. Specifically, there are 1,630 cases in which sharq beta and expression predictions are concordant with one another but discordant with what is reported in the SRA. Of these, 1,099 samples (67.4%) include the predicted tissue in the reported tissue (i.e. predicted tissue is 'brain'; reported tissue is 'brain mixed human brain'). Of the remaining 531 (531/1,099, 32.6%) samples concordant between sharq beta and expression predictions but discordant with reported tissue, there are a number of explanations. To assess what could be going on, we randomly sampled one sample from each of the 31 unique studies from which these 531 samples were generated. Of these 31 samples, (1) 51.6% of the time (16/31) the predicted tissue were a more general term for the reported tissue (i.e. predicted tissue is brain; reported tissue is 'dorsolateral prefrontal cortex'), (2) 25.8% (8/31) of the time the reported tissue was concordant with the predicted tissue, but the reported tissue also included diagnosis (predicted tissue is 'prostate';
reported tissue is 'prostate cancer tissue'), (3) 9.7% of the time (3/31) the tissue was coded differently within the SRA for that study (i.e. predicted tissue is 'blood', reported tissue is 'serum'), or (4) 12.9% of the time the predictions are discordant (i.e. predicted tissue is 'liver'; reported tissue is 'brain'). Taken together these data suggest that true accuracy is likely between the lower bound of 47.1% determined by comparison to sharq beta predictions and the 82.1% accuracy found in this less rigid comparison to the subset of SRA samples with defined tissue annotations.
Sequencing strategy prediction
Technical sequencing information, such as whether single or paired end sequencing was carried out, is important information for accurate downstream analysis. As the GTEx and TCGA data were all sequenced using a single sequencing strategy, they could not be used to generate the predictor.
Instead, to predict this phenotype, the SRA data were randomly split into a training set (N=24,829) and a test set (N=24,828). Eighty regions that distinguished single end sequencing libraries from paired end sequencing libraries were identified and the predictor built. In the training set, the resubstitution error was 10.5%. Accuracy was then assessed in the SRA test samples (N=24,828), GTEx (9,538), and TCGA (N=11,284) samples, where accuracy for sequencing strategy prediction was 89.1%, 99.9%, and 94.1%, respectively ( Figure 3C ).
While the error rates within the SRA training and test sets are higher than the sex and tissue predictors, this is unsurprising, as this predictor was built in the more heterogeneous SRA samples, where errors in reported phenotypes are more likely and expression data were generated across a number of labs. To test this directly, we compared cases in which predicted and reported sequencing strategy were discordant to samples predicted to have been misreported. Misreported sequencing strategy was calculated independent of expression estimation by comparing the number of reads counted by Rail-RNA [10] and comparing it to the number of spots reported in the SRA. If the sample was reported to be 'single end' sequencing but the counted reads value exceeded the number of spots reported, the sample was determined to have a misreported 'single end' sequencing strategy when it should have been 'paired end'. Conversely, for samples labeled paired end where there were exactly twice the number of spots as reads counted, this was determined to be a case where a sample was misreported as 'paired end' when it should have been 'single end'. In the SRA training data, of the 224 samples determined to likely be misreported, 201 (89.7%) were also identified as discordant in the expression predictions, independently confirming misreporting in these studies. Similarly, in the SRA test data, 234 of the 251 (93.2%) samples determined to have been misreported were also discordant between reported and predicted sequencing strategy, further confirming misreporting of sequencing strategy within a subset of the studies in the SRA and suggesting that accuracy reported herein is a lower bound.
Sample source prediction
To utilize data from a human RNA-seq experiment, it is critical the analyst be aware whether the data were generated from tissue directly or from a cell line. were utilized. Prediction accuracy was 89.2% in these data. Applying this predictor across the GTEx (N=9,538) and TCGA (N=11,284) data, demonstrated its accuracy to be 96.1% and 99.8%, respectively ( Figure 3D ).
Age prediction
In an attempt to predict age, 40 regions associated with age were selected from the GTEx training data using a random forest approach. In the training data, predicted age and actual age were highly correlated (R 2 =0.956); however, in the GTEx training data, these regions were not predictive of age Figure 2 ). This initial attempt to predict age was carried out agnostic to sample tissue of origin. To alternatively test if age could be predicted within tissue, regions associated with age were identified across a number of tissues. Given the limited strength of this relationship ( Supplementary Figure 3 ), we did not pursue prediction of age from expression data by this approach further. As such, age predictions have not been included for use. As with age, some phenotypes will likely be better identified through other means -either by manual curation of SRA metadata or through natural language processing [17] .
Variance in prediction across data sets
This approach to prediction utilizes simple modeling and interpretable predictors; however, the trade-off for simplicity is that extreme expression estimates in future data sets could pose a problem for accurate prediction. To assess this as a potential issue, we calculated the variance for each of the 40 regions used for sex prediction across each data set as a test case. Two patterns are discernible from the variance across data sets for these 40 regions ( Supplementary Figure 4) . First, we note that there is generally more variance within the TCGA and SRA data relative to the GTEx samples. As the TCGA samples contain cancer expression data and the SRA samples are extremely heterogeneous, both of which are expected to increase variance in expression estimates, this result is unsurprising. Secondarily, across the 40 sex prediction regions, expression variance is largely similar across data sets at regions used for sex prediction, suggesting that extreme outliers is largely not an issue. However, there are a few regions that demonstrate increased variance in the TCGA and SRA data. Given the overall sex prediction accuracy, this finding suggests that even when more extreme variance is seen within a data set, it does not prohibit prediction. While more extreme variance does not largely affect accuracy within sex prediction, a predictor which directly addresses or controls for these extreme values at the sample level may see improved accuracy.
Assessing discordance
For each predicted phenotype, we report prediction accuracies for samples within each dataset (GTEx, TCGA, SRA). By including information about the accuracy of our predictions we make it possible for downstream models to incorporate this uncertainty. While the overall accuracy for any of the predicted phenotypes assessed was at minimum ≥85%, assessing phenotype accuracy at the sample level is non-trivial. When available, we have included reported phenotype, but this information may not be available for many samples or may be incomplete or incorrect. Phenotype files often use manual data entry and can themselves be prone to error [18] . For example, when we look at the 15 GTEx samples whose reported sex and predicted sex disagree ( Supplementary Table   S2 ), 13 of these samples come from the same individual ("GTEX-11ILO"). Further, no samples from this individual had a predicted sex concordant with the sample's reported sex. Together, this may mean that this sample has mislabeled sex information. The remaining two samples ("SRR809065" and "SRR658331"), each have 12 other tissue samples from the same subject. In both cases, the other 12 samples were predicted to be the reported sex, supporting that these two samples are either incorrect predictions or mislabeled samples that should likely not be used for further analyses.
2.9 Use case #1: Sex Analysis within the SRA There is a long history within the biomedical sciences favoring the study of males relative to females [14, 15] . To assess the prevalence of this bias within the SRA, we have analyzed the overall breakdown of sex in a number of ways. First, we report that overall within the SRA, 58.6% of the samples are predicted to be female, 34.4% are predicted to be male, and 7.4% could not be disambiguated, suggesting that there is no evidence for a male sex bias within the SRA. However, one important caveat is that we do not yet have a handle on how many replicate samples there are within the SRA. Looking specifically at the largest study within the SRA (SRP025982, N=1720) [19] , it becomes clear that this study, in assessing the accuracy and reproducibility of RNA-Seq across platforms and labs, analyzed the same samples, which happened to be female, many times. of studies include some combination of predicted sexes ( Figure 4A ). For projects where predicted sex includes samples that are either female and unassigned or male and unassigned, one could reasonably assume that in many of these cases, all samples were likely of one biological sex; however, we will leave it up to future investigators to decide if this is a fair assumption to make for their purposes. Finally, we note, that samples sizes within each study vary from one sample to more than 1500 samples, with the largest study including almost exclusively samples predicted to be female ( Figure 4B ). 
Use case #2: Using predicted phenotypes to identify studies of interest
There is a wealth of expression data within recount2 [9] ; however, with regards to phenotype information, it is only currently possible to filter on information contained within the abstract.
Using predicted phenotypes can help to filter out and identify studies of interest to a particular researcher.
For example, we were interested in identifying a cancer study in which sex was not reported.
We hoped to assess the effect of including predicted sex in the analysis of these data. To identify such a study, we filtered through cancer studies included in the SRA to identify studies fulfilling the following criteria: expression data (1) predicted to be generated from paired end sequencing,
(2) where sex was not reported, (3) where the data were predicted to have come from a tissue (rather than a cell line), and finally (4) that had at least 20 samples. Upon applying these filters, we identified three studies within the SRA meeting these criteria.
Use case #3: Using predicted phenotypes in analyses
Having identified studies of potential interest, we moved forward with study SRP029880 to assess the utility of the phenotypes we predicted (see Methods). This study includes expression data from 54 samples from 18 unique individuals. For each individual, RNA-seq was carried out on a normal colonic epithelial sample (NC), the primary colon cancer epithelium (PC), and a metastatic cancer sampled from the lung (MC). The initial analysis sought to identify gene expression changes that correspond to aggressiveness of colorectal cancer (CRC). To do so, they authors carried out differential gene expression analyses between NC and MC samples (identifying 2,861 significant genes) and between MC and PC samples (identifying 1,846 significant genes). Significance was defined such that p < 0.001 and logF C ≥ 2. No covariates were included for analysis. The authors then, in an attempt o remove the effects of the fact that the MC samples were sampled from the lung while the PC and NC samples were sampled from the colon, filtered out "liver specific genes (309 genes)" using the TiGER database [20] from their results.
Here, with prediction data available, we can directly and appropriately correct for tissue differences between samples and include sex in the differential gene expression analysis (DGEA). Given the experimental design, we checked to ensure that, for each individual, the same sex was predicted across each of the three samples. Predicted sex was concordant across samples within individual for 17/18 (94.4%) of the samples included for study. (Sample 22 was predicted to be female in one sample and male in the other two). Analysis was first carried out as in the initial publication [21] , comparing NC:PC and MC:PC. We note, however, that expression data utilized herein were downloaded from recount2 [9] . Thus, rather than using normalized FPKM, as was done in Kim et al., expression was instead summarized by first scaling the gene counts (see Methods Section 4.14)
and then log2 transforming those values. These expression estimates were used to carry out DGEA using the same software and cutoffs as in Kim et al [21] . Despite using the same software, settings, and thresholds used in Kim et al. [21] , fewer genes (82.8% and 71.3% less in MC:PC and NC:PC, respectively) were detected to be significantly differentially expressed in our analysis ( Figure 5A ).
As a result, all further comparisons utilized the DGEA results from our analysis, both with and without covariate inclusion to remove the impact of the discrepancy in number of genes identified.
To assess the effects of covariate inclusion on the analysis, DGEA was carried out with either predicted sex or both predicted sex and predicted tissue as covariates. A final analysis was carried out where both predicted sex and predicted tissue were included as covariates. For each of the NC and PC samples, predicted tissue was either "colon" or "small intestine." Interestingly, within the MC samples, which were sampled from the liver, seven were predicted to be "small intestine", the site of the primary lesion, and eleven to be "liver", the site of the metastases. Interestingly, cancer cell lines do not always recapitulate the tissue from which they were derived, suggesting that cell lines derived from metastases could, in certain cases, recapitulate the primary tissue from which they were derived [23, 24] . Here, these findings suggest, unsurprisingly, that the same may be the case at the tissue level. Thus, if the MC samples were all simply labeled 'liver', not only would the results change but the analysis would be completely confounded by tissue. In this case, using predicted phenotypes allows for the most appropriate differential gene expression analysis to be carried out.
The effects of covariate inclusion were assessed using concordance at the top (CAT) plots [22] comparing concordance between genes identified as significant with and without covariate inclusion.
Upon inclusion of sex as a covariate in the analysis, the results remain largely unchanged, where 9 of the 10 most significant genes and all 100 of the top 100 genes between analysis are concordant for the MC:PC comparison and 8 of 10 and 96 of 100 genes are concordant for the NC:PC comparison ( Figure 5B ). However, upon inclusion of both predicted sex and predicted tissue, the results are dramatically different, with concordance at only 6 of the 10 most significant genes and 53 of the top 100 genes between analyses ( Figure 5C ). As the MC samples were obtained from a completely different tissue, this finding suggests that many (40-47%) of the differences reported as significant between MC and PC samples simply reflect tissue differences between the samples, rather than differences associated with cancer aggressiveness.
Conclusions
We demonstrate that accurate phenotype prediction from expression data is possible for both biological and technical phenotypes and demonstrate, through three use cases, how predicted phenotypes can be utilized going forward. We have built predictors for sequencing strategy, sex, sample origin, and tissue. These predictors have been applied to the samples within recount2 [9] and can be applied to expression data generated in the future. Predicted phenotypes were generated using the R package phenopredict and can be accessed in the R package recount using the add predictions() function. We demonstrate how predicted phenotypes can be used to characterize the samples currently within recount2, to identify samples and studies of interest for future study, and how predicted phenotypes can be incorporated into analyses to improve accuracy. Taken together, the availability of this critical phenotype information across the 70,000 samples currently
Sample summary
Human samples processed using Rail-RNA [10] and incorporated into recount2 
Region level expression data summary
For prediction, as to not limit the sites to expression at annotated regions of the genomes, expressed region (ER) [16, 7] level data were utilized. All GTEx samples were normalized to a library size of 40 million 100 base-pair reads to compute the mean coverage, as available from recount2 [9] .
Expressed regions were defined using a cutoff of 0.5 with the findRegions() derfinder [7] 
General approach to prediction
The GTEx data are well-characterized and are comprised of various tissue samples having been generated from the same individual. Given the study design and well-characterized nature of these data, when possible (sex, tissue), the GTEx expression data were used to build the phenotype predictors. When invariability of a phenotype within GTEx limited this approach (sample origin, sequencing approach), the SRA data were used to train the predictor. The first step of our general approach was to randomly sample half of the training data set. Expression data from this subset of individuals comprised our training set. For each predictor, accuracy was then assessed in samples from three tests sets: (1) The remaining samples from the training data set that were not used to build the predictor (2) TCGA, and (3) the data set not used to build the predictor either SRA (in the case of sex and tissue) or GTEx (in the case of sample origin and sequencing strategy).
Accuracy was assessed by comparing the predicted phenotype to the reported phenotype in any sample for which this information was available. Upon achieving sufficient prediction accuracy (≥85% in both the training and the first test set defined above), phenotypes were then predicted across all samples within recount2.
R package: phenopredict
We have built the R package phenopredict which can use expression data and phenotype information from any study to build a phenotype predictor. Functionality within this package allows for (1) regions to be selected for the phenotype of interest (select regions()), (2) a predictor to be built for either continuous or categorical variables (build predictor()), (3) the predictor in to be tested on the training data to assess resubstitution error (test predictor()), (4) for data to be extracted from a new data set for the same regions upon with the predictor was built (extract data()), and (5) for phenotype prediction in this new data set (predict pheno()). Additionally, for analyses in which data have to be extracted across multiple files (i.e. across chromosomes), there is a function (merge input()) to merge across the output of select regions() prior to building the predictor.
Region selection: select regions()
Within the training data, where phenotype information is available, the first step is to identify expressed regions associated with the phenotype of interest. To accomplish this, select regions() in phenopredict was used.
Continuous variables: Regions are identified within select regions() by employing a linear model within limma's lmFit() framework [26] . In this framework, phenotype is regressed upon expression such that:
where Y is the continuous phenotype. X r is the design matrix with the expression values for each region and optionally other covariates, and α 0tr and α rt are the coefficients relating the expression of region r to phenotype t. To ensure predictors herein were as generalizable across data sets as possible, no covariates were included during region selection; however, functionality exists within phenopredict to include covariates. We use limma to moderate variances across the regions tested, thus shrinking region-wise sample variances. These moderated variances are utilized in identification of regions most highly associated with the phenotype of interest. We then pick the top s t most significant regions using the topTable() function from limma. The number of regions to select is specified by the user.
Categorical variables: The same approach as above (equation 1) is carried out for each level in the phenotype. For each level of the phenotype we create a vector of indicator variables Y t such that Y it is an indicator that is one if sample i is level t and zero otherwise. We then follow the modeling procedure described above to select the top regions.
Building the predictor: build predictor()
Categorical variables: Coefficient estimates are calculated for each level in the phenotype of interest. Using expression from the selected regions and the phenotype of interest as input, validationCellType() from the R package minfi [27] is used to fit the model:
where S is the set of all selected regions across levels of the phenotype for categorical variables.
We fit the model subject to the condition that β rt > 0∀β rt .
Continuous variables:
A parallel random forest is used to build the predictor in the training data where the features are the selected expressed regions {X} S and the outcome is the phenotype vector Y.
Random forests for continuous variables were constructed using parRF method within the R package caret [28] . The model was provided with both expression estimates for the selected regions and covariate information, if desired. In the case of age, prediction was attempted both with and without covariate (sex, BMI, and tissue) inclusion, to ensure accuracy could not be improved upon covariate inclusion. The fits from this model are output for prediction.
resubstitution error: test predictor()
Categorical variables: To assess prediction accuracy in the training data, where truth is known, predictions are made from the predictor built in equation 2. test predictor() makes predictions from the expression data and coefficients generated in build predictor() using the framework established in projectCellType() from minfi [27, 29] . For each sample, the likelihood the sample is each level in the phenotype is calculated. Predicted phenotype is subsequently assigned to the most likely level within the phenotype. If two levels within the phenotype receive the same estimate, the sample is predicted as "unassigned." Finally, this function reports (1) predicted phenotypes,
(2) reported phenotypes, and (3) resubstitution error, where:
Resubstitution Error = 1 − # of samples predicted correctly # of samples predicted * 100
Continuous variables: Predictions are made from the random forest model's fits. Here, this was carried out using predict() in R. Accuracy was assessed using the correlation coefficient (R 2 ) and root mean square error (RMSE) between the reported and predicted values.
Extracting regions in a new data set: extract data()
Before prediction can be carried out in a new data set, expression data at the precise regions used to build the predictor must be extracted. extract data() can be used to obtain expression estimates in a new data set at the same eact regions selected by select regions() and used to build the predictor. By using expression from a fixed set of genomic regions in the new data set, rather than identifying a new set of predictive regions, we limit the possibility of overfitting our model.
Phenotype prediction: predict pheno()
Categorical variables: Phenotype prediction in a new data set occurs as in test prediction() with the exception that expression data in this case comes from a new expression data set (X new ).
These expression data are from an independent set of samples but include information for the same regions (r) as were characterized in the data set (X r ) used to build the predictor.
Continuous variables: Fits calculated by build predictor() from the random forest model are then applied to these data and predicted phenotypes are provided.
Assessing accuracy
Categorical variables: The subset of samples within each data set for which reported phenotypes were available were used to assess accuracy, such that: Accuracy = # of samples predicted correctly # of samples predicted * 100
Here, the number of samples predicted includes all samples for which phenotype information was available and whose reported value was included in our predictor (see Supplementary Table S1 ).
Using sex as an example, all SRA samples whose sex was reported as "male", "M", "Male", "m", "female", "F", "Female", or "f" were included in the denominator. However, samples whose reported sex was missing (NA) or whose reported value was not meaningful (i.e."not collected", "not determined", "Unknown", etc.) were not included in the calculation of accuracy. Sex was, however, predicted across all samples after accuracy assessment.
Continuous variables: Accuracy was again assessed using the correlation coefficient (R 2 ) and RMSE between the reported and predicted values, for samples where information was available.
Integration with recount2
Predicted phenotypes are available through the R package recount. 
Use case #2: Using predicted phenotypes to identify studies of interest
Predicted phenotypes can be used to identify samples or studies of interest for future study. To exemplify this, constraints were placed on the predicted phenotype data to search for a study within the cancer studies in recount2 requiring that possible projects must (1) employ paired RNA-seq,
(2) not have reported sex included in the study's metadata, (3) have tissue a predicted sample source (rather than be derived from a cell line), and (4) have at least 20 samples in the study.
Studies fitting these criteria were considered for use in Use case #3.
Use case #3: Using predicted phenotypes in analyses
After identifying two studies in case study #2 that fit our criteria, the corresponding abstracts for each study were searched within recount2 [9] . Not only did SRP027530 have a smaller sample size (N SRP 027530 = 20; N SRP 029880 = 54), but the abstract of these data included the breakdown of females and male samples [30] . Thus, despite the fact that sex was not directly reported in and accessible from the SRA metadata, a quick search made it clear that sex could be relatively easily obtained for this study. As we were interested in studying the effects of sex on an analysis that otherwise did not include sex in their analysis, we moved to study SRP029880.
Gene-level count data were downloaded from recount2 [9] for project SRP029880. Raw counts were scaled to the total coverage of the sample. Cancer status (NC, PC, MC) and sample id were obtained from the reported SRA metadata field 'title'. Differential gene expression analysis was first carried out as reported in the initial publication [21] . Briefly here, DGEA was carried out using the edgeR [31] R package, which assumes a negative binomial distribution for expression to detect differentially expressed genes. Both normal colon epithelium (NC) and lung metastases (MC) were compared to primary colorectal tissue (PC) samples. To recapitulate the analysis from the initial publication, no outlier genes or samples were removed, no covariates were included, and no adjustment was made for the fact that the PC samples were used in both comparisons.
As was done in the initial publication, to protect against hypervariable genes driving differences detected gene dispersion was estimated for the log2 scaled gene counts for 58,037 genes across 54 samples (18 unique individuals). For each gene (using the estimated dispersions calculated), and each comparison (NC:PC, MC:PC) a negative binomial generalized log-linear model (glm) was fit.
To be in line with the initial publication [21] , genes were considered statistically significant if the p-value was <0.0001 and the log fold change (logFC) was ≥2.
To assess the effects of covariate inclusion on this analysis the same analysis as above was carried out with the exception that covariates were included. First, the inclusion of predicted sex as a covariate on the analysis was assessed. Secondarily, the inclusion of predicted sex and tissue was assessed. In line with expectation, within this study, samples were predicted to be either 'small intestine', 'colon' or 'liver'. Samples predicted to be either 'colon' or 'small intestine' were combined into the umbrella category 'intestine'. DGEA was carried out as above. To note, however, tissue only varies in the MC:PC comparison, where both liver and colon samples were analyzed.
Accordingly, this analysis was carried out for the MC:PC comparison and not NC:PC, where all samples were from the colon.
To compare across the three DGEA (no covariates, sex, and sex + tissue), for each of the two cancer comparisons (NC:PC and MC:PC), concordance among genes determined to be significantly differentially expressed were assessed. Concordance at the top (CAT) plots [22] , where the number of significant genes in common between the analyses being compared is visualized, were generated.
Availability of data and materials
Analyses were all carried out in R 3.3.1. Code for the R package phenopredict is available at https://github.com/leekgroup/phenopredict. Code for prediction of each phenotype is available at https://github.com/ShanEllis/phenopredict_phenotypes. Use case code is available at https://github.com/ShanEllis/phenopredict_usecase. 
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